David Tai

4.5k total citations · 2 hit papers
76 papers, 1.8k citations indexed

About

David Tai is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Tai has authored 76 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 30 papers in Hepatology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Tai's work include Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Pancreatic and Hepatic Oncology Research (12 papers). David Tai is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Pancreatic and Hepatic Oncology Research (12 papers). David Tai collaborates with scholars based in Singapore, United States and South Korea. David Tai's co-authors include Su Pin Choo, Shue‐Shian Chiou, Yun‐Fan Liaw, Chi‐Sin Changchien, Valerie Chew, Joycelyn Jie Xin Lee, Connie Yip, Yun Hua Lee, Armando Santoro and Pierce K. H. Chow and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

David Tai

72 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

2024 75 citations Peter R. Galle, Thomas Decaens et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Tai Singapore	21	737	522	354	306	302	76	1.8k
Anne Huynh France	28	593 0.8×	229 0.4×	625 1.8×	107 0.3×	196 0.6×	130	2.7k
Christopher Siegel United States	21	751 1.0×	269 0.5×	535 1.5×	259 0.8×	179 0.6×	51	2.4k
Ran Reshef United States	27	995 1.4×	141 0.3×	350 1.0×	106 0.3×	393 1.3×	140	2.3k
Marshall T. Schreeder United States	27	788 1.1×	327 0.6×	482 1.4×	311 1.0×	360 1.2×	103	2.1k
Stéphane Cattan France	18	355 0.5×	729 1.4×	278 0.8×	211 0.7×	1.1k 3.8×	36	2.3k
David A. Smith United Kingdom	19	420 0.6×	170 0.3×	194 0.5×	506 1.7×	206 0.7×	53	1.5k
T.R. Hakala United States	18	1.1k 1.5×	214 0.4×	180 0.5×	129 0.4×	639 2.1×	53	2.3k
Alexander Chung Singapore	15	565 0.8×	752 1.4×	323 0.9×	346 1.1×	374 1.2×	34	1.8k
M Nalesnik United States	18	894 1.2×	279 0.5×	137 0.4×	87 0.3×	596 2.0×	28	1.9k
P. J. Johnson Hong Kong	17	927 1.3×	530 1.0×	484 1.4×	283 0.9×	345 1.1×	34	2.1k

Countries citing papers authored by David Tai

Since Specialization

Citations

This map shows the geographic impact of David Tai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Tai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Tai more than expected).

Fields of papers citing papers by David Tai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Tai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Tai. The network helps show where David Tai may publish in the future.

Co-authorship network of co-authors of David Tai

This figure shows the co-authorship network connecting the top 25 collaborators of David Tai. A scholar is included among the top collaborators of David Tai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Tai. David Tai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tan, Hwee Leong, Kennedy Yao Yi Ng, Joycelyn Jie Xin Lee, et al.. (2025). Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Controlled Trials. Annals of Surgical Oncology. 32(6). 4094–4107. 2 indexed citations

Lin, Chia‐Chi, Giuseppe Curigliano, Armando Santoro, et al.. (2024). Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study. BMJ Open. 14(8). e079132–e079132. 8 indexed citations

Galle, Peter R., Thomas Decaens, Masatoshi Kudo, et al.. (2024). Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.. Journal of Clinical Oncology. 42(17_suppl). LBA4008–LBA4008. 75 indexed citations breakdown →

Kim, Hyung‐Don, Ho Yeong Lim, Baek‐Yeol Ryoo, et al.. (2024). Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nature Medicine. 30(3). 699–707. 29 indexed citations

Lau, Mai Chan, Chun Jye Lim, Xinru Lim, et al.. (2023). Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma. Frontiers in Immunology. 14. 1150985–1150985. 13 indexed citations

Tabernero, Josep, Eric Van Cutsem, Elena Garralda, et al.. (2023). A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-MutantKRASWild-Type Metastatic Colorectal Cancer. The Oncologist. 28(3). 230–238. 34 indexed citations

Kamath, Suneel D., David Tai, Irene Moreno, et al.. (2023). Abstract OT3-24-01: ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer. Cancer Research. 83(5_Supplement). OT3–24.

Kim, Stéfano, et al.. (2023). 989P Disease etiology and efficacy outcomes with atezolizumab plus bevacizumab (atezo-bev) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Multinational retrospective analysis. Annals of Oncology. 34. S609–S610. 1 indexed citations

Kaya, Neslihan Arife, Jianbin Chen, Hannah Lai, et al.. (2022). Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma. Theranostics. 12(10). 4703–4717. 4 indexed citations

10.

Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3620–3629. 257 indexed citations breakdown →

11.

Yoo, Changhoon, Jwa Hoon Kim, Min‐Hee Ryu, et al.. (2021). Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Liver Cancer. 10(2). 107–114. 68 indexed citations

12.

Lee, Joycelyn Jie Xin, David Tai, & Su Pin Choo. (2021). Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. ESMO Open. 6(3). 100129–100129. 11 indexed citations

13.

Tong, Aaron Kian Ti, et al.. (2020). Molecular Imaging and Therapy of Liver Tumors. Seminars in Nuclear Medicine. 50(5). 419–433. 3 indexed citations

14.

Lee, Yun Hua, David Tai, Connie Yip, Su Pin Choo, & Valerie Chew. (2020). Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Frontiers in Immunology. 11. 568759–568759. 100 indexed citations

15.

Teo, Jin Yao, John Carson Allen, David Chee Eng Ng, et al.. (2018). Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. Surgery. 163(5). 1008–1013. 8 indexed citations

16.

Tan, Hwee Leong, Claramae Shulyn Chia, Grace Hwei Ching Tan, et al.. (2017). Gastric peritoneal carcinomatosis - a retrospective review. World Journal of Gastrointestinal Oncology. 9(3). 121–121. 30 indexed citations

17.

Tai, David, Keith Wells, John J. Arcaroli, et al.. (2015). Targeting the WNT Signaling Pathway in Cancer Therapeutics. The Oncologist. 20(10). 1189–1198. 118 indexed citations

18.

Chua, Clarinda, Iain Beehuat Tan, Yasuhide Yamada, et al.. (2015). Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 76(2). 397–408. 29 indexed citations

19.

Tai, David, et al.. (2012). The impact of Irritable Bowel Syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterology. 12(1). 104–104. 45 indexed citations

20.

Koo, Yu Xuan, Matthew Zirui Tay, Yii Ean Teh, et al.. (2011). Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Annals of Hematology. 90(10). 1219–1223. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact